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OBJECTIVES: The advantages of improved adherence to
immunosuppression include reduced morbidity, mortality, and
health care costs. Our aim was to examine calcineurin inhibitor
(CNI) adherence following kidney transplantation and the effect
on hospital days and health care costs. METHODS: US claims
data from 10 US health plans for de novo patients receiving
kidney transplants between 1995 and 2005 were employed.
Patients with ≥ one post-transplant claim for cyclosporine mod-
iﬁed (CsA) or tacrolimus (tac) were included. CNI adherence was
deﬁned as the medication possession ratio (MPR) or the number
of therapy days supplied to the number of followup days during
the year following the ﬁrst CNI claim. Patients who switched to
another CNI medication or were not continuously enrolled in
the health plan were excluded. Zero-inﬂated negative binomial
regression was used to examine the relationship between CNI
adherence and hospital days. RESULTS: Of 821 enrolled
patients, 51% were in the CsA and 49% in the tac cohorts. The
groups were not different with regard to age, gender, income,
level of comorbidity, or number of hospital days during the
adherence measurement period. A total of 28% of the CsA group
was 100% adherent (MPR = 1) compared to 21% in the tac
group (p = 0.02). Holding patient characteristics and prior uti-
lization constant, receiving CsA was associated with 15 (95%
CI: 5, 40) fewer hospital days compared to tac. Also, increasing
levels of adherence by one standard deviation reduced days spent
in the hospital by 12 (95% CI: 9, 30). This difference in hospi-
tal days likely impacted total health care costs, which were sig-
niﬁcantly lower for CsA ($13,949) compared to tac ($20,896)
during the same period (p = 0.009). CONCLUSIONS: Receiv-
ing cyclosporine modiﬁed following transplantation was associ-
ated with higher levels of adherence, fewer hospitalizations, and
lower total health care costs.
PUK3
BUDGET IMPACT ANALYSIS OF INCLUDING RENAL
REPLACEMENT THERAPY IN THE BENEFIT PACKAGE OF
UNIVERSAL COVERAGE IN THAILAND
Kasemsup V, Prakongsai P,Tangcharoensathien V
International Health Policy Program—Thailand, Nonthaburi,Thailand
OBJECTIVES: To estimate the amount of government health
budget required for the extension of access to renal replacement
therapy (RRT) towards beneﬁciaries of the universal health care
coverage (UC) scheme in Thailand. Ability of the government to
bear the increasing budget and appropriate measures to cope
with anticipated costs of including RRT in the beneﬁt package
were also investigated. METHODS: Literature review on
demand for RRT at both domestic and international levels, and
the estimate of costs for haemodialysis and continuous peritoneal
dialysis in Thailand. From the government perspective, several
scenarios of budget requirements according to the estimated
costs for RRT and possible rationing criteria were calculated.
RESULTS: The government would spend approximately more
than ﬁve billion Baht during the ﬁrst year of implementation, if
there is neither strategy to reduce the costs for RRT nor appro-
priate selection criteria for end-stage renal disease patients. The
budget for universal access to RRT would increase to 74,355
million Baht in the sixteenth year of implementation if the gov-
ernment played passive roles in controlling costs of the program.
The budget required would reduce to 58% of the estimate if the
government introduced the rationing criteria for patients aged
less than 60 years. CONCLUSIONS: The policy on the exten-
sion of access to RRT should be considered carefully by the gov-
ernment because of its ﬁnancial impact on the government health
budget. Appropriate interventions including effective measures
to control costs of RRT, strategies to reduce the incidence of end-
stage renal disease, and the rationing criteria for access to RRT
are needed if the decision to implement the policy is made.
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OBJECTIVES: Despite concerns regarding bioequivalence of
NB-CsA to B-CsA, generics constitute the second most widely
used form of CsA in the US. We assessed whether potential cost
savings associated with the lower acquisition cost of generics are
realized with NB-CsA. METHODS: Claims data from eight
commercial health plans were linked to Organ Procurement
Transplant Network data. De novo kidney recipients with ≥1
pharmacy claim for B-CsA (n = 247) or NB-CsA (n = 64) were
included. Information was collected for 1 year before and after
initial (index) CsA claim. Patients who switched between study
drugs or had <1 year pre- or post-index data were excluded. Log
transform regression with backward selection was used to model
costs in the ﬁrst year post-index. Statistical signiﬁcance of cohort
differences in predicted costs was determined by bootstrapping
with 1000 repetitions. RESULTS: Baseline demographics were
similar between the two cohorts; 62% male, 60% age >45 years,
and 10% African American. Total prescription medication costs
were higher for NB vs. B-CsA ($14,233 vs. $12,606, p = 0.04),
reﬂecting higher costs for both immunosuppressant (IS) and non-
IS drugs incurred by the NB-CsA cohort. NB-CsA patients had
higher inpatient costs ($17,459 vs. $7904), more hospitalizations
(4.5 vs. 3.2, respectively), and slightly higher outpatient costs
($8547 vs. $7477) vs. B-CsA. Utilization for gastrointestinal
symptoms (e.g., abdominal pain, vomiting, diarrhea) was higher
in the NB vs. B-CsA cohort (13% vs. 5%, p = 0.04) as were total
health care costs ($40,239 vs. $27,988, p = 0.07). After con-
trolling for patient characteristics and pre-transplant costs, total
costs were 27% higher (p = 0.03) for NB vs. B-CsA. For the
average patient taking NB vs. B-CsA, predicted costs were $8291
higher (95% CI: $122, $21,278). CONCLUSIONS: Despite
lower acquisition cost of generics, de novo renal transplant recip-
ients initiated on NB-CsA incurred increased health care costs,
which appeared to be driven by costly pharmacy and inpatient
utilization.
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OBJECTIVES: The study objective was to assess costs and the
cost effectiveness of early and late epoetin administration in
chronic renal insufﬁciency during the predialysis period in
Poland. METHODS: The analysis was based on clinical data
from systematic literature review. Only direct medical costs were
included into the study. The effectiveness was expressed as death
or dialysis avoided. The cost-effectiveness analysis from the
payer perspective was conducted. RESULTS: The mean individ-
ual treatment cost of early and late epoetin administration in
chronic renal insufﬁciency during the predialysis period was esti-
mated for €3597 (1 € = 4.035 PLN) and €2163, respectively. The
cost of death or dialysis avoided in the early and late introduced
epoetin treatment amounted to €5058 and €4429, respectively.
However 14% increment of this equation in patients early
treated with epoetin resulted in over 50% decrement of end point
appearance (initiation of dialysis or death). CONCLUSIONS:
For the majority of patients early treatment with epoetin trans-
lates into signiﬁcant delay of renal replacement therapy. Early
introduction of epoetin treatment in chronic renal insufﬁciency
patients before dialysis is cost-effective.
PUK6
COST-EFFECTIVENESS OF TREATMENT WITH EPOIETIN
ALPHA FOR PATIENTS WITH ANAEMIA DUE TO RENAL
FAILURE—THE CASE OF SWEDEN
Glenngård AH1, Schön S2, Persson U3
1The Swedish Institute for Health Economics, IHE, Lund, Sweden,
2Ryhov County Hospital, Jönköping, Sweden, 3The Swedish Institute
for Health conomics, IHE, Lund, Sweden
Anaemia is a common complication of renal failure. Anaemia
can be treated with erythropoietin (EPO) administration, RBC
transfusion, or a combination of both. EPO has been registered
for treatment of renal anaemia in Sweden since the beginning of
the 1990s, and is the primary treatment regimen for anaemia
related to renal failure. OBJECTIVE: The objective of this study
was to carry out a cost-effectiveness analysis of treatment with
epoietin alpha compared to treatment with RBC transfusion for
patients with anaemia associated with renal failure in Sweden.
METHOD: Incremental costs associated with EPO treatment
compared with the traditional treatment therapy of blood trans-
fusion (costs of EPO, iron supplementation, administration and
surveillance, EPO complications and costs of blood transfusion)
are estimated. Swedish treatment guidelines, patient characteris-
tics and unit costs (provider perspective) are used throughout the
study. Information about QALY gains is collected from the lit-
erature. RESULTS: The estimated cost per QALY gained from
administration of EPO to renal patients in Sweden was found to
be SEK 403,921 (EUR 43,201) on average. The cost of treatment
with EPO differs widely between haemodialysis (HD) and peri-
tonealdialysis (PD) patients due to different dosages of EPO and
iron supplementation. The results were found to be sensitive
regarding assumptions on QALY gains but not regarding the cost
of blood transfusion. CONCLUSION: The estimated cost per
QALY falls within the range acceptable of the value of a QALY
in Sweden for both HD and PD patients. EPO administration to
renal patients is much more costly in Sweden than in the UK,
primarily due to higher dosage of EPO and iron supplementa-
tion in Sweden. Swedish patients, on the other hand reach higher
Hb-levels than patients in the UK.
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Benign prostatic hyperplasia (BPH) is common in older men
affecting 40% of men in their ﬁfties. If the enlarged gland begins
to press upon the urethra and to interfere with urination, then
treatment may be needed. Transurethral resection of the prostate
(TURP) is a minimally invasive treatment that has became the
gold standard for patients who are unwilling to remain on med-
ication or in whom medical therapy failed. Recently a minimally
invasive surgery treatment has shown similar results compared
to TURP, transurethral needle ablation of the prostate (PROS-
TIVA®). OBJECTIVES: To carry out an economic evaluation of
PROSTIVA® vs. TURP in non-drug respondent BHP patients in
the Spanish setting. METHODS: A Markov model was devel-
oped in order to simulate the clinical and economical conse-
quences of using PROSTIVA® or TURP in BHP. Four health
states were considered: Intervention, therapeutic success, non-
therapeutic success and permanent adverse events through a
cost-effectiveness analysis. Clinical and economical data were
retrieved from published clinical trials and validated by a clini-
cian experienced in the BHP management. Perspective of the
analysis was the National Health System perspective, so only
direct costs were included. The time horizon was 15 years with
6 months cycles, so clinical and economical results were dis-
counted at a 3% per year. A probabilistic sensitivity analysis
(PSA) was performed in order to check the variability in the
model results. All uncertain variables included were included in
PSA. RESULTS: Mean cost per patient with PROSTIVA® was
€1207 (p = 0.00) less than patients treated with TURP, but with
a decrement 0.42 QALYs (p = 0.00), which leads us to an ICER
of €2860/QALYs. Sensitivity analyses have shown consistent
results across changes in all variables. CONCLUSION: PROS-
TIVA® compared to TURP has shown to be an efﬁcient therapy
for non-drug respondents BHP patients in Spain, with an ICER
below accepted thresholds.
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BPH and associated lower urinary tract symptoms affect quality
of life of older men and could require surgery. The MTOPS study
demonstrated that the risk of overall clinical progression (includ-
ing worsening of symptoms, acute urinary retention, urinary
incontinence, renal insufﬁciency, or recurrent urinary infection)
was signiﬁcantly reduced by ﬁnasteride (−34%, p = 0.002), dox-
azosin (−39%, p < 0.001) and by the combination of both 
(−66%, p < 0.001), as compared with placebo. The clinical
beneﬁt of the combination was signiﬁcantly higher than the one
of each individual component. MTOPS study showed also that
only ﬁnasteride, alone or in combination with doxazosin reduced
signiﬁcantly (p < 0.001) the risk of invasive therapy by respec-
tively 64% and 67% compared with placebo. OBJECTIVE: To
estimate the cost-efﬁcacy of ﬁnasteride, doxazosin, and the com-
bination of both in the treatment of BPH in the perspective of
